Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million

Core Viewpoint - Vivoryon Therapeutics N.V. has signed a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global, LP for up to EUR 15 million to support its clinical development efforts, particularly for its Phase 2b study in diabetic kidney disease [2][3][4] Financing Agreement Details - The SEPA allows Yorkville to purchase up to EUR 15 million of ordinary shares over 36 months, with Vivoryon having the right to sell shares in individual tranches [3] - Each tranche can include shares equal to 100% of the average daily trading volume over the previous five trading days, with a maximum of 389,359 shares per tranche, subject to mutual consent for increases [4] - Shares will be issued at a 5% discount to the prevailing market price, and an additional 167,028 shares will be issued to Yorkville as a commitment fee [4] Use of Funds - Funds raised through the SEPA will be utilized for ongoing business operations, preparation for the Phase 2b study of varoglutamstat, and advancing preclinical studies of the new candidate VY2149 [5] Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing small molecule medicines targeting pathologically altered proteins, with a pipeline that includes treatments for Alzheimer's disease, kidney disorders, and cancer [6]